iCAD, Inc. (ICAD)
NASDAQ: ICAD · Real-Time Price · USD
2.700
-0.130 (-4.59%)
At close: Feb 21, 2025, 4:00 PM
2.660
-0.040 (-1.48%)
After-hours: Feb 21, 2025, 4:11 PM EST
iCAD, Inc. Revenue
iCAD, Inc. had revenue of $4.22M in the quarter ending September 30, 2024, with 3.54% growth. This brings the company's revenue in the last twelve months to $18.94M, up 10.03% year-over-year. In the year 2023, iCAD, Inc. had annual revenue of $17.32M, down -12.54%.
Revenue (ttm)
$18.94M
Revenue Growth
+10.03%
P/S Ratio
3.76
Revenue / Employee
$274,493
Employees
69
Market Cap
71.16M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 17.32M | -2.48M | -12.54% |
Dec 31, 2022 | 19.80M | -13.84M | -41.13% |
Dec 31, 2021 | 33.64M | 3.94M | 13.27% |
Dec 31, 2020 | 29.70M | -1.64M | -5.24% |
Dec 31, 2019 | 31.34M | 5.72M | 22.32% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ICAD News
- 3 days ago - iCAD To Showcase Five AI-Powered Research Presentations Advancing Breast Cancer Detection, Risk Evaluation, and Breast Arterial Calcification Assessment at ECR 2025 - GlobeNewsWire
- 26 days ago - iCAD Pre-Announces Estimated Q4 2024 Revenue - GlobeNewsWire
- 5 weeks ago - Izotropic Announces Team Leading Clinical Study Design and FDA Regulatory Submissions - Newsfile Corp
- 2 months ago - SABCS 2024: New Research Assesses iCAD's Image Based AI-Risk, Detection, and Breast Arterial Calcifications (BAC) Assessment Across Diverse Populations - GlobeNewsWire
- 2 months ago - CORRECTION – iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and ProFound Health Partnership with Cascaid Health at RSNA 2024 - GlobeNewsWire
- 3 months ago - iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and a Second-Read AI Partnership with Cascaid Health at RSNA 2024 - GlobeNewsWire
- 3 months ago - iCAD, Inc. (ICAD) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - iCAD Reports Financial Results for Third Quarter Ended September 30, 2024 - GlobeNewsWire